Gia Nemsadze

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 301 citations · Full text

Medicine, Oncology, Pharmacology +15

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze et al. · Journal of Thoracic Oncology · 2023 · 98 citations · Full text

Medicine, Oncology, Pharmacology +15

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki et al. · The Lancet Oncology · 2024 · 80 citations

Medicine, Oncology, Pharmacotherapy +17

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Tamta Makharadze, Ruben G.W. Quek, Tamar Melkadze et al. · Cancer · 2023 · 16 citations · Full text

Medicine, Oncology, Pharmacology +15